NEWS CENTER
SCROLL
Dec 17, 2025
17/ 12
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
Dec 15, 2025
15/ 12
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
Nov 10, 2025
10/ 11
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
Sep 15, 2025
15/ 09
Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
Apr 21, 2025
21/ 04
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Mar 17, 2025
17/ 03
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
EXPLORER MORE
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...